Pharma's pipeline economics are brutal: longer discovery cycles, pricier trials, manufacturing that can't miss a batch. The companies compounding advantage move data through the GxP perimeter faster than their peers — discovery reusing clinical, manufacturing learning from deviations, evidence generated once and used everywhere. Efficiency inside the regulated envelope is the transformation.
Every engagement runs the same arc: a short discovery with the people who own the problem, an architecture you can challenge before anything is built, then weekly increments shipped at production quality from the first sprint. We stay through go-live, instrument what we ship, and hand over a system your own team can run — with the documentation to prove it.
